Clinical trial NCT01504178: Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease
Official title: Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Parkinson's Disease
Keywords: Noradrenergic system and pain in Parkinson's disease
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
Collaborators: name: French Parkinson Association
First posted: 2012-01-05
Enrollment: 28
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Patients suffering from Parkinson's disease (PD) frequently experienced painful sensations that could be, in part, due to a central modification of nociception mechanisms. Previous studies have shown that pain perception was altered in Parkinson's disease (subjective and objective pain thresholds and pain-induced cerebral activity) and that administration of L-Dopa normalized this alteration. In the central nervous system, L-Dopa is converted in dopamine and in norepinephrine. Apomorphine (a dopamine agonist) has no effect on pain threshold and pain-induced cerebral activity. Therefore the noradrenergic system could be involved in pain alteration in PD.

To assess the role of noradrenergic system in pain in patients with PD, we chose duloxetine (norepinephrine and serotonin reuptake inhibitor)because a recent study had shown that duloxetine allowed an improvement of pain clinical scores (pain questionnaires) in patients with PD.

36 patients will be enrolled in this study. We supposed that a chronic intake of duloxetine increase the pain perception level compare to the placebo. This increase would be the same than those observed with L-Dopa.


Eligibility criteria: Inclusion Criteria:

* Patients with clinical diagnosis of Parkinson's disease according to the criteria of the UKPDSBB
* Parkinson's disease patients with a score ≤ 3 on the Hoehn and Yahr scale
* Patients treated with dopaminergic antiparkinsonian drugs (L-Dopa, dopamine agonists, ICOMT...)
* Patients affiliated to a social protection program
* Women with efficacy contraception

Exclusion Criteria:

* Patients suffering from another pathology causing chronic pain (rheumatic disease, traumatic or orthopedic pathologies...)
* Parkinson's disease patients with a score \> 3 on the Hoehn and Yahr scale
* Depressed patients (MADRS score \< 16)
* Patients suffering from a cancer
* Patients under tutelage, curatella or law protection
* Patients with a complete contraindication against apomorphine injections or duloxetine administration (selective serotonin reuptake inhibitor and monoamine oxydase inhibitors)
* Patients without any control of their arterial hypertension
* Patients with a neuroleptic treatment
* Pregnant women

Primary outcomes:
measure: Subjective pain threshold determined using thermal stimulations (thermotest) with the method of levels
timeFrame: One month
Secondary outcomes:
measure: Objective pain threshold determined recording the nociceptive reflex of flexion
timeFrame: One month
measure: Clinical evaluation of the severity of the motor handicap of patients using the Unified Parkinson's Disease Rating Scale (UPDRS III)
timeFrame: One month
Other outcomes:
Locations:
city: Toulouse
country: France
facility: CIC, Purpan Hospital
Study officials:
affiliation: Purpan hospital, Toulouse
name: Christine Brefel-Courbon, MD
role: PRINCIPAL_INVESTIGATOR
References: